Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review.
10.5468/ogs.2018.61.4.524
- Author:
Myeong Seon KIM
1
;
Chel Hun CHOI
;
Tae Joong KIM
;
Jeong Won LEE
;
Jeeyun LEE
;
Duk Soo BAE
;
Byoung Gie KIM
Author Information
1. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bksong.kim@samsung.com
- Publication Type:Case Report
- Keywords:
Melanoma;
Pembrolizumab;
Antibodies, monoclonal, humanized;
Uterine Cervical Neoplasms
- MeSH:
Adult;
Antibodies, Monoclonal, Humanized;
Biopsy;
Cervix Uteri*;
Diagnosis;
Female;
Gynecological Examination;
Humans;
Hysterectomy;
Immunotherapy;
Lung;
Lymph Node Excision;
Melanoma*;
Prognosis;
Rare Diseases;
Uterine Cervical Neoplasms;
Vagina;
Vaginal Discharge
- From:Obstetrics & Gynecology Science
2018;61(4):524-528
- CountryRepublic of Korea
- Language:English
-
Abstract:
Malignant melanoma of the genital tract is a rare disease that is usually diagnosed by chance. When a definite diagnosis is delayed, the prognosis is very poor without standardized treatment. Herein, we describe a 40-year-old patient who presented with a history of bloody vaginal discharge for 7 months. Gynecological examination showed an exophytic, hard and pigmented cervical mass involving the upper vagina. The patient was diagnosed with cervical melanoma after a punch biopsy and underwent a radical hysterectomy, upper vaginectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy. After surgeries, the patient underwent 2-cycles of adjuvant immunotherapy with pembrolizumab, but died within 8 months. In this report, treatment with pembrolizumab after radical surgery was not effective for this patient who had a primary cervical melanoma that metastasized to bone and lung tissue. We do not know why pembrolizumab was ineffective for this patient, but there are several possible explanations; further research is needed.
